These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28126367)

  • 1. The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth.
    Society for Maternal-Fetal Medicine (SMFM) Publications Committee
    Am J Obstet Gynecol; 2017 Mar; 216(3):B11-B13. PubMed ID: 28126367
    [No Abstract]   [Full Text] [Related]  

  • 2. Are we stopping preterm birth trials too early?
    Byrne R; Mol B
    Am J Obstet Gynecol; 2016 Jan; 214(1):134-5. PubMed ID: 26363485
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply.
    Rozenberg P; Winer N
    Am J Obstet Gynecol; 2016 Jan; 214(1):135. PubMed ID: 26348377
    [No Abstract]   [Full Text] [Related]  

  • 4. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
    Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
    Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 17-α hydroxyprogesterone caproate for the prevention of preterm birth.
    Gupta S; Roman AS
    Womens Health (Lond); 2012 Jan; 8(1):21-30. PubMed ID: 22171770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
    Hall NR
    Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
    Manuck TA
    Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
    O'Brien JM; Lewis DF
    Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing Barriers to 17-Hydroxprogestrone Caproate (17P) Injections to Prevent Recurrent Preterm Birth in Mississippi.
    Bofill JA; Collier CH; Pearson M; Shwayder JM; Morrison JC
    J Miss State Med Assoc; 2016 Nov; 57(11):350-351. PubMed ID: 30281234
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
    Gonzalez-Quintero VH; Cordova YC; Istwan NB; Tudela F; Rhea DJ; Romary LM; Marimon A; Desch CN; Stanziano GJ
    Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 17 OHPC for prevention of preterm birth in twins: back to the drawing board?
    Durnwald CP
    Am J Obstet Gynecol; 2013 Mar; 208(3):167-8. PubMed ID: 23433323
    [No Abstract]   [Full Text] [Related]  

  • 12. Reducing preterm births.
    Reprod Biomed Online; 2007 May; 14(5):663. PubMed ID: 17509212
    [No Abstract]   [Full Text] [Related]  

  • 13. The safety of progestogen in the prevention of preterm birth: meta-analysis of neonatal mortality.
    Ahn KH; Bae NY; Hong SC; Lee JS; Lee EH; Jee HJ; Cho GJ; Oh MJ; Kim HJ
    J Perinat Med; 2017 Jan; 45(1):11-20. PubMed ID: 27124668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
    Mackeen AD; Rafael TJ; Zavodnick J; Berghella V
    Am J Perinatol; 2013 Oct; 30(9):755-8. PubMed ID: 23341330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerclage, progesterone and α-hydroxyprogeterone caproate treatment in women at risk for preterm delivery.
    Haram K; Mortensen JH; Morrison JC
    J Matern Fetal Neonatal Med; 2014 Nov; 27(16):1710-5. PubMed ID: 24678618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence?
    Barton JR; Barton LA; Istwan NB; Rhea DJ; Desch CN; Sibai BM
    Am J Obstet Gynecol; 2011 Sep; 205(3):269.e1-6. PubMed ID: 22071060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
    Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K
    Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO; Stamilio DM; Macones GA; Polsky D
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
    Co AL; Walker HC; Hade EM; Iams JD
    Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
    Coleman S; Wallace L; Alexander J; Istwan N
    J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.